EPKINLY
![Roche's Columvi and AbbVie's Epkinly: The Battle for Breakthroughs in Large B-Cell Lymphoma Treatment](https://pharmtales.com/wp-content/uploads/2023/06/Roches-Columvi-and-AbbVies-Epkinly_-The-Battle-for-Breakthroughs-in-Large-B-Cell-Lymphoma-Treatment.jpg)
Roche’s Columvi and AbbVie’s Epkinly: The Battle for Breakthroughs in Large b Cell Lymphoma Treatment
SG Tylor
Roche’s Columvi (glofitamab) receives FDA accelerated approval for treatment of Large b Cell Lymphoma, sparking a rivalry with AbbVie and ...
![Epkinly: First And Only Fda-Approved Bispecific Antibody For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)](https://pharmtales.com/wp-content/uploads/2023/06/Epkinly-First-And-Only-Fda-Approved-Bispecific-Antibody-For-Relapsed-Or-Refractory-Diffuse-Large-B-Cell-Lymphoma-Dlbcl-1.jpg)
Epkinly: FDA-Approved Bispecific Antibody for DLBCL
SG Tylor
On May 19, 2023, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted approval to EPKINLYTM (epcoritamab-bysp) as ...